129564-34-7 Usage
General Description
2-(2,6-Dichlorophenyl)acetohydrazide is a chemical compound with the molecular formula C8H9Cl2N3O. It is a hydrazide derivative used in the synthesis of various pharmaceutical drugs. 2-(2,6-DICHLOROPHENYL)ACETOHYDRAZIDE is known to possess anti-tubercular and antimicrobial properties and is also used as a potential anti-inflammatory agent. It acts by inhibiting the release of inflammatory mediators such as leukotriene B4 and prostaglandin, making it useful in the treatment of various inflammatory conditions. It is also being investigated for its potential in the treatment of Alzheimer's disease. However, the compound also has potential health hazards and should be handled with care, as it is toxic if swallowed or inhaled, and may cause skin and eye irritation.
Check Digit Verification of cas no
The CAS Registry Mumber 129564-34-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,9,5,6 and 4 respectively; the second part has 2 digits, 3 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 129564-34:
(8*1)+(7*2)+(6*9)+(5*5)+(4*6)+(3*4)+(2*3)+(1*4)=147
147 % 10 = 7
So 129564-34-7 is a valid CAS Registry Number.
InChI:InChI=1/C8H8Cl2N2O/c9-6-2-1-3-7(10)5(6)4-8(13)12-11/h1-3H,4,11H2,(H,12,13)
129564-34-7Relevant articles and documents
From docking false-positive to active anti-HIV agent
Barreiro, Gabriela,Kim, Joseph T.,Guimar?es, Cristiano R. W.,Bailey, Christopher M.,Domaoal, Robert A.,Wang, Ligong,Anderson, Karen S.,Jorgensen, William L.
, p. 5324 - 5329 (2007)
Virtual screening of the Maybridge library of ca. 70 000 compounds was performed using a similarity filter, docking, and molecular mechanics- generalized Born/surface area postprocessing to seek potential non-nucleoside inhibitors of human immunodeficienc
NOVEL AZOLES AND RELATED DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS) IN ANTIVIRAL THERAPY (HIV)
-
Sheet 1, (2009/03/07)
The present invention relates to novel heterocyclic compounds, including oxadiazole compounds, pharmaceutical compositions and their use in the inhibition of reverse transcriptase and the treatment of HIV (1 and 2) infections, AIDS and ARC and other viral
